CPC A61K 39/42 (2013.01) [C07K 16/10 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61P 31/14 (2018.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2760/20111 (2013.01)] | 34 Claims |
1. A method of preventing and/or treating a RABV and/or non-RABV lyssavirus infection in a subject, wherein the method comprises administering to a subject in need thereof an antibody, or an antigen binding fragment thereof, that neutralizes a lyssavirus infection, wherein the antibody or antigen binding fragment comprises heavy chain CDRH1, CDRH2, and CDRH3 amino acid sequences and light chain CDRL1, CDRL2, and CDRL3 amino acid sequences as set forth in SEQ ID NOs: 165-169 and 171, respectively, or in SEQ ID NOs: 165-168 and 170-171, respectively.
|